Christina Godwin, MD
Urology · Mankato, MNNPI 1932494630
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Medtronic at 59.3% of the total. Reporting peaked in 2019 at $2,192 and has fallen 74.3% since, to $564 in 2025.
Across 54 payments — averaging $104.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Coloplast$1K
- Boston Scientific$198
- Bluewind Medical$159
- Valencia Technologies Corporation$156
- Calyxo, Inc.$138
- plus $374 from 11 others
Across 18 payments — averaging $2586.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bluewind Medical$47K
What the payments were for
- Consulting fees$1,92034%
- Travel & lodging$1,04418%
- Food & beverage$2,63447%
- Education$561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 16 | $3,353 |
| Coloplast | 15 | $1,275 |
| Boston Scientific | 4 | $198 |
| Bluewind Medical | 2 | $159 |
| Valencia Technologies Corporation | 1 | $156 |
| Calyxo, Inc. | 1 | $138 |
| Intuitive Surgical | 1 | $82 |
| AbbVie | 3 | $68 |
| Astellas Pharma US Inc | 1 | $52 |
| Urogen Pharma, Inc. | 2 | $36 |
| Johnson & Johnson | 1 | $33 |
| Dendreon Pharmaceuticals LLC | 2 | $26 |
| Coopersurgical, Inc. | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Axonics, Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,654 in reported general payments places this provider in the 85th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 118 | $91,476 |
| MyrbetriqMirabegron | 75 | $42,985 |
| Estradiol | 180 | $12,158 |
| Methenamine Hippurate | 169 | $10,287 |
| Trospium Chloride | 142 | $4,708 |
| Solifenacin Succinate | 194 | $3,891 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 71 | $3,561 |
| Potassium Citrate ErPotassium Citrate | 61 | $2,285 |
| Tolterodine Tartrate ErTolterodine Tartrate | 36 | $1,707 |
| Tamsulosin Hcl | 109 | $736 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 53 | $678 |
| Oxybutynin Chloride ErOxybutynin Chloride | 29 | $649 |
| Cephalexin | 69 | $534 |
| NitrofurantoinNitrofurantoin Macrocrystal | 17 | $533 |
| Chlorthalidone | 39 | $491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $91,476118 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $42,98575 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 urology providers in Minnesota.
Other urology in Mankato
- David YangMankato$298K
- Steven BernsteinEdina$271K
- Ayman SoubraMinneapolis$204K
- Sean ElliottMinneapolis$163K
- Jonathan WarnerRochester$144K
- Steven SiegelWoodbury$140K
- Aaron MilbankWoodbury$97K
- Tobias KohlerRochester$89K
- Joseph MahonEdina$86K
- Nissrine NakibMinneapolis$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.